FDA Lists Guidance Documents Planned for 2013
FDA has released a list of more than 50 guidance documents planned for 2013.
FDA has released a list of more than 50 guidance documents planned for 2013. The list reflects guidance documents currently under development as of the date of the posting, Jan. 31, 2013. Planned documents relevant to cGMP and compliance include:
- Quality Systems Approach to Pharmaceutical cGMP Regulation (OMPQ)
- Uniformity of In-Process Mixtures (OMPQ)
- Control of Highly Potent Compounds (OMPQ)
- Contract Manufacturing Arrangements for Drugs: Quality Agreements
- Submission of Field Alert Reports and Biological Product Deviation Reports (OMPQ)
- Pre-Launch Activities Importation Request (PLAIR)
With regards to biosimilars, the agency plans a guidance on Submission of Clinical Pharmacology Data as Evidence of Biosimilarity for Biologics and Protein Products, as well as one titled Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants.
Other guidance documents in the planning stage include Securing the Drug Supply Chain—Standards for Tracking and Tracing Prescription Drug Packages, and a guidance on compounded medications titled Pharmacy Compounding of Human Drugs Under Section 503A of the Federal Food, Drug, and Cosmetic Act.
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
